Pacific Biosciences of California, Inc.
PACB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $502 | $2,488 | $1,837 | $4,166 |
| - Cash | $55 | $180 | $325 | $461 |
| + Debt | $672 | $934 | $948 | $955 |
| Enterprise Value | $1,119 | $3,242 | $2,460 | $4,661 |
| Revenue | $154 | $201 | $128 | $131 |
| % Growth | -23.2% | 56.3% | -1.7% | – |
| Gross Profit | $37 | $53 | $49 | $59 |
| % Margin | 24.2% | 26.3% | 38.2% | 45.1% |
| EBITDA | -$243 | -$271 | -$282 | -$251 |
| % Margin | -157.6% | -135.2% | -220% | -192.1% |
| Net Income | -$310 | -$307 | -$314 | -$181 |
| % Margin | -201.2% | -153% | -244.9% | -138.9% |
| EPS Diluted | -1.07 | -1.21 | -1.4 | -0.89 |
| % Growth | 11.6% | 13.6% | -57.3% | – |
| Operating Cash Flow | -$206 | -$267 | -$263 | -$111 |
| Capital Expenditures | -$6 | -$9 | -$17 | -$6 |
| Free Cash Flow | -$212 | -$275 | -$280 | -$117 |